This page is for reference only. We are no longer offering this service.

COVID-RUO Profiling

Power Your Discoveries in a Truly Unparalleled Fashion

Achieve Higher Resolution. Greater Specificity. Unmatched Reproducibility Multiplex Profiling of 14 SARS-CoV-2 Proteins

Ideal For

Long-haul and Longitudinal COVID studies

Analysis of samples for profiles associated with disease severity

(e.g. mild vs. severe)

Distinguishing pathogen cross-over to determine true cases of COVID

Multivariate analysis

Serimmune SERA Technology

Robust and Reproducible

  • 96-well throughput, standardized pipelines and established confidence intervals and run standards

Monitors all SARS-CoV-2 proteins with single amino acid resolution across the entire proteome

Multi-target detection performed at one time

State-of-the-Art Reference Database

  • Compare any sample relative to our database of thousands of pre-pandemic controls
  • Truly disambiguate signal vs. noise
  • Reduce false positives

Highly interactive, intuitive and easy-to-understand customer report

Customer Report

A list of 52 motifs identified as sensitive and specific to SARS-CoV-2 positive patients and the related enrichment scores are provided for each sample.

Samples are compared to a pre-pandemic/healthy control, a COVID positive subject cohort and a COVID vaccine recipient cohort. Results are provided in an easy-to-understand and interactive html format.

Raw data that includes Motifs with Enrichment Scores and IWAS values for each amino acid in the SARS-CoV-2 proteome to allow for more in-depth analysis by the customer.

COVID-RUO Profiling Service Sample Report

How it Works

Customer Provides

50 ul of serum or plasma per sample

Minimal information about the samples


Analyzes each sample for IgG antibodies using its 10 billion member, random 12mer, bacterial peptide display library

Performs epitope analysis across the entire SARS-CoV-2 Proteome using its proprietary IMUNE and PIWAS methodologies

Provides summary data and visualizations for each sample, including raw data for subsequent customer analysis

“Due to the flexibility of the SERA platform, we rapidly predicted that the B.1.1.7 variant is unlikely to escape antibodies generated against linear epitopes in prior SARS-CoV-2 infections.

This is the tip of the iceberg for what Serimmune can do. I am excited to continue to collaborate with the team.”

Dr. Akiko Iwasaki

Waldemar Von Zedtwitz Professor of Immunobiology and Molecular, Cellular and Developmental Biology and HHMI Investigator at Yale School of Medicine

Frequently Asked Questions

Results are typically delivered within 2 weeks.

Samples should be shipped frozen on dry ice or at 2-8 Deg on cold packs for overnight delivery.

100 ul is preferred if IgG and IgM are run. 50 ul is acceptable if only IgG is run.

No, samples should not be diluted. We dilute the sample 1:25 in the assay.

An enrichment value is calculated for each peptide epitope that is similar to an antibody titer. The combination of antibody affinity and concentration both contribute to this value.

In precision studies, the CVs for serology panels are generally <10%.

This is a custom service, but we can look at epitopes against arbitrary strains or variants.

SERA vs. Antibody sequencing
Antibody sequencing does not provide information on the functional targets of the antibody, it only provides the sequence and quantity of antibody species.

Array-based technologies
Array-based technologies and other technologies such as Virscan focus on specific proteomes or meta-proteomes. Because of the random nature of the SERA library, every sample processed can be leveraged for specificity and cross-reactivity analyses. New strains or variants can be analyzed without redesign of the library.

SERA vs. Peptide arrays
Antigen based peptide arrays are limited to the exact linear amino acid sequences contained in the proteome. By contrast, SERA utilizes a random peptide library that can capture linear epitopes as well as non-mapping, conformational epitopes.

SERA vs. Protein arrays
Protein arrays utilize whole proteins that are very expensive to develop and may exhibit lower specificity compared to peptide-based antibody detection.

Read Our COVID Paper